ANDA 90523, held by Novast Labs Ltd. Ethinyl Estradiol; Norgestimate.
As of Nov 16, 2026, ANDA 90523 (Mono-Linyah), held by Novast Labs Ltd, was first approved by FDA on May 23, 2012, with 4 approved supplements and 0 published complete response letters.
Mono-Linyah is a combination of norgestimate, a progestin, and ethinyl estradiol, an estrogen, indicated for use by females of reproductive potential to prevent pregnancy. 1.1 Oral Contraceptive
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 23, 2012 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Mono-Linyah0.035MG;0.25MG · tablet;oral-28 | Ethinyl Estradiol; Norgestimate | Rx |
| Apr 29, 2022 | Supplement 9Labeling · Standard review | Approved | None posted |
| Feb 3, 2022 | Supplement 3Labeling · Standard review | Approved | None posted |
| Nov 5, 2020 | Supplement 6Labeling · Standard review | Approved | None posted |
| Dec 19, 2014 | Supplement 1Manufacturing | Approved | None posted |
| May 23, 2012 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters